GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
GMI-1271, a specific E-selectin inhibitor is being evaluated in the
company's ongoing Phase 1/2 clinical trial, in which clinicians are
evaluating the use of GMI-1271 along with chemotherapy in patients with
relapsed or refractory AML as well as those with newly diagnosed AML. Earlier
this month, the company announced that GMI-1271 had been granted
Breakthrough Therapy designation by the
"The European orphan designation will provide incentives for the
commercialization and development of GMI-1271 in AML, where there are
limited therapies available to patients," said
The
About AML
AML is a cancer of the blood and bone marrow. AML is the most common
type of acute leukemia in adults. The
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate, GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the completion of ongoing clinical trials and the initiation of
future clinical trials, whether interim results from a clinical trial
will be predictive of the final results of the trial or results of early
clinical trials will be indicative of the results of future trials,
expectations for regulatory approvals, availability of funding
sufficient for GlycoMimetics' foreseeable and unforeseeable operating
expenses and capital expenditure requirements, other matters that could
affect the availability or commercial potential of GlycoMimetics' drug
candidates and other factors discussed in the "Risk Factors" section of
GlycoMimetics' Annual Report on Form 10-K that was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170525005579/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media